Dr. Minxiang Gu

Hematology
1 Hospital Dr, 
Columbia, MO 
1 Hospital Dr, 
Columbia, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Minxiang Gu is a Hematologist in Columbia, Missouri. Dr. Gu is rated as an Experienced provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Myelodysplastic Syndrome (MDS), Large-Cell Immunoblastic Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in MO
Hospital Affiliations
University Of Missouri Health Care
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

THE CURATORS OF THE UNIVERSITY OF MISSOURI
1 Hospital Dr, Columbia, MO 65212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: April 05, 2023
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Advanced in Squamous Cell Lung Carcinoma
Dr. Umasankar Ramadoss
Hematology Oncology | Oncology | Hematology
Advanced in Squamous Cell Lung Carcinoma
Dr. Umasankar Ramadoss
Hematology Oncology | Oncology | Hematology

Missouri Cancer Care Pharmacy

1705 E Broadway, 
Columbia, MO 
 (1.2 miles away)
573-874-7800
Languages Spoken:
English
See accepted insurances

Umasankar Ramadoss is a Hematologist Oncology specialist and an Oncologist in Columbia, Missouri. Dr. Ramadoss is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Bone Marrow Aspiration, and Liver Embolization.

Advanced in Squamous Cell Lung Carcinoma
Dr. Elangovan Balakrishnan
Hematology Oncology | Hematology | Oncology
Advanced in Squamous Cell Lung Carcinoma
Dr. Elangovan Balakrishnan
Hematology Oncology | Hematology | Oncology

Missouri Cancer Care Pharmacy

1705 E Broadway, Suite 100, 
Columbia, MO 
 (1.2 miles away)
573-874-7800
Languages Spoken:
English
See accepted insurances

Elangovan Balakrishnan is a Hematologist Oncology specialist and a Hematologist in Columbia, Missouri. Dr. Balakrishnan is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Paget Disease of the Breast, Bone Marrow Aspiration, and Endoscopy.

Advanced in Squamous Cell Lung Carcinoma
Dr. Michael C. Trendle
Hematology Oncology | Hematology | Oncology
Advanced in Squamous Cell Lung Carcinoma
Dr. Michael C. Trendle
Hematology Oncology | Hematology | Oncology

Bothwell Regional Health Center

601 E 14th St, Bothwell Regional Health C, 
Sedalia, MO 
 (51.0 miles away)
660-826-8833
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Trendle is a Hematologist Oncology specialist and a Hematologist in Sedalia, Missouri. Dr. Trendle is rated as a Distinguished provider by MediFind in the treatment of Squamous Cell Lung Carcinoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Trendle is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gu's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 37 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile